merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Lilly's vials are positioned as a safer, FDA-approved alternative to compounded drugs, which have less oversight.</answer>

<question_number>2</question_number>
<answer>LillyDirect offers direct delivery of FDA-approved vials, mirroring the convenience of telehealth companies but with regulatory credibility.</answer>

<question_number>3</question_number>
<answer>Compounded drugs lack FDA oversight for safety, quality, and effectiveness.</answer>

<question_number>4</question_number>
<answer>It targets price-sensitive customers currently using compounded versions, reclaiming them from competitors even at lower profit margins.</answer>

<question_number>5</question_number>
<answer>Compounding pharmacies can legally produce tirzepatide only while it remains on the FDA shortage list; Lilly aims to remove this justification.</answer>

<question_number>6</question_number>
<answer>Cutting out third-party supply chains enables transparent, lower pricing directly to consumers.</answer>

<question_number>7</question_number>
<answer>Medicare’s non-coverage may drive older patients to riskier compounded options despite Lilly’s safer vials.</answer>

<question_number>8</question_number>
<answer>Patients may perceive Lilly’s vials as safer due to FDA approval, shifting away from compounded alternatives.</answer>

<question_number>9</question_number>
<answer>Tirzepatide is listed as "in shortage" by the FDA.</answer>

<question_number>10</question_number>
<answer>Undercutting competitors on price to signal reclaiming market share.</answer>